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The SNAT2 (SLC38A2) System A amino acid transporter mediates Na+-coupled
cellular uptake of small neutral α-amino acids (AAs) and is extensively regulated in
response to humoral and nutritional cues. Understanding the basis of such regulation
is important given that AA uptake via SNAT2 has been linked to activation of
mTORC1; a major controller of many important cellular processes including, for
example, mRNA translation, lipid synthesis, and autophagy and whose dysregulation
has been implicated in the development of cancer and conditions such as obesity
and type 2 diabetes. Extracellular AA withdrawal induces an adaptive upregulation
of SNAT2 gene transcription and SNAT2 protein stability but, as yet, the sensing
mechanism(s) that initiate this response remain poorly understood although interactions
between SNAT2 and its substrates may play a vital role. Herein, we have explored how
changes in substrate (AA and Na+) availability impact upon the adaptive regulation
of SNAT2 in HeLa cells. We show that while AA deprivation induces SNAT2 gene
expression, this induction was not apparent if extracellular Na+ was removed during
the AA withdrawal period. Furthermore, we show that the increase in SNAT2 protein
stability associated with AA withdrawal is selectively repressed by provision of SNAT2
AA substrates (N-methylaminoisobutyric acid and glutamine), but not non-substrates.
This stabilization and substrate-induced repression were critically dependent upon
the cytoplasmic N-terminal tail of SNAT2 (containing lysyl residues which are putative
targets of the ubiquitin-proteasome system), because “grafting” this tail onto SNAT5,
a related SLC38 family member that does not exhibit adaptive regulation, confers
substrate-induced changes in stability of the SNAT2-5 chimeric transporter. In contrast,
expression of SNAT2 in which the N-terminal lysyl residues were mutated to alanine
rendered the transporter stable and insensitive to substrate-induced changes in protein
stability. Intriguingly, SNAT2 protein stability was dramatically reduced in the absence
of extracellular Na+ irrespective of whether substrate AAs were present or absent. Our
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findings indicate that the presence of extracellular Na+ (and potentially its binding to
SNAT2) may be crucial for not only sensing SNAT2 AA occupancy and consequently
for initiating the adaptive response under AA insufficient conditions, but for enabling
substrate-induced changes in SNAT2 protein stability.
Keywords: SNAT5, adaptive regulation, sodium ion, amino acid sensing, transporter, System A
INTRODUCTION
The System A amino acid (AA) transporter family is comprised
of three isoforms, SNAT1, 2, and 4, of which SNAT2 (SLC38A2)
is the most widely expressed and most extensively regulated
(Mackenzie and Erickson, 2004). SLC38 family members mediate
the sodium ion-coupled uptake of short chain neutral AAs
some of which (e.g., methionine and threonine) are considered
nutritionally indispensable, whereas others (e.g., alanine and
glutamine) are important for intermediary tissue metabolism
and inter-organ flow of carbon and nitrogen (Hundal, 1991).
Members of this carrier family exhibit tolerance for AAs with
N-methyl substitutions such as N-methylaminoisobutyric acid
(Me-AIB); a property that has proved useful in discriminating
System A isoforms from other AA transporters and functionally
characterizing the SLC38 family. SNAT2-mediated AA transport
is highly pH sensitive (Baird et al., 2006), modulated by
glucocorticoids and, in skeletal muscle cells, acutely stimulated
by growth factors and insulin by a process that involves
recruitment of intracellular SNAT2 molecules to the plasma
membrane (Hundal et al., 1994; Hyde et al., 2002). Cellular
expression/activity of SNAT2 is also elevated in response
to hyperosmotic stress, which stimulates uptake of organic
osmolytes (AAs) and establishes an osmotic gradient for
water movement that helps normalize cell volume and reduce
intracellular ionic strength (Bussolati et al., 2001; Lopez-
Fontanals et al., 2003; Bevilacqua et al., 2005). The secondary
active transport of extracellular AAs results in an outwardly
directed concentration gradient of SNAT substrates that we
have shown can subsequently exit the cell via tertiary exchange
transporters, such as System L, which operate alongside SNAT
carriers in the plasma membrane (Baird et al., 2009; Hundal
and Taylor, 2009). This tertiary exchange coupling is of
particular significance as it influences the intracellular delivery
of essential AAs (e.g., leucine) that have a potent stimulatory
effect on mTORC1, a signaling complex regulating key cellular
processes such as mRNA translation, cell growth/metabolism,
and autophagy (Saxton and Sabatini, 2017). Consequently,
it follows that factors affecting expression and activity of
SNAT2 may also impact on mTORC1 activation and regulation
of these latter processes (Pinilla et al., 2011; Uno et al.,
2015).
Another major feature of SNAT2 is its cellular upregulation
in response to extracellular AA limitation (Kilberg et al., 1985;
Guma et al., 1992; Hyde et al., 2001). Such upregulation is a
property shared by a group of genes involved in AA biosynthesis
(e.g., asparagine synthase) and transport and normally referred
to as adaptive regulation. As such, this phenomenon involves the
GCN2/ATF4 pathway, which helps coordinate a suppression in
global protein synthesis and an increase in the expression of select
transport proteins (e.g., SNAT2) that help facilitate recovery
of cell volume and AAs once the availability of extracellular
AAs has been restored (Kilberg et al., 2005). The transcriptional
increase in SNAT2 gene expression is dependent upon an AA
responsive domain in the first intron of the SLC38A2 gene by
ATF4 (Palii et al., 2006). However, in addition to the genomic-
driven increase in SNAT2, we have previously shown that the
adaptive increase in SNAT2 also involves enhanced stabilization
of the SNAT2 protein (Hyde et al., 2007). This increase in
stability is not seen for SNAT5, a structurally related transporter
from the SLC38 gene family, which does not tolerate Me-
AIB as a substrate or exhibit adaptive regulation. Strikingly,
the increase in SNAT2 protein stability induced in response to
AA withdrawal is associated with an isoform-specific regulatory
domain(s) present within the hydrophilic N-terminal region,
given that expression of a SNAT2–SNAT5 chimera in which the
SNAT5 N-terminal domain is substituted with that of SNAT2
promotes stabilization of the chimeric (SNAT2-5) protein upon
AA withdrawal (Hyde et al., 2007). Intriguingly, the functional
increase in System A/SNAT transport activity seen in response
to extracellular AA withdrawal can be repressed by resupply
of any one single SNAT2 substrate AA even when all other
AAs remain absent (Hyde et al., 2007). Since non-substrates
do not exert this repressive effect on System A adaptation, the
observations indicate that SNAT2 possesses a dual “transceptor”
function in which occupancy of the SNAT2 substrate-binding site
not only initiates transmembrane AA transfer but also enables
sensing of AA sufficiency that is linked to regulation of SNAT2
expression and stability. We have previously demonstrated that
single provision of SNAT2 substrate AAs to AA-starved cells
represses the adaptive increase in SNAT2 gene promoter activity
(Hyde et al., 2007), but hitherto it remains unknown whether
substrate-induced repression of SNAT2 also entails reduced
SNAT2 protein stability. In this study, we have explored the
effects of substrate (AA and sodium) availability on SNAT2
transcription and protein stability. Our findings reveal that the
presence of extracellular sodium is crucial for inducing the
transcriptional increase in SNAT2 gene expression in response to
AA withdrawal and for maintaining expression and stability of
SNAT2 protein.
MATERIALS AND METHODS
Materials
Culture media [Dulbecco’s Modified Eagle’s Medium (DMEM)],
fetal calf serum (FCS), and antibiotic/antimycotic solution
were from Invitrogen (Paisley, United Kingdom). AAs
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and reagent grade chemicals were from Sigma–Aldrich
(Poole, United Kingdom). Inhibitors were from Tocris
(Bristol, United Kingdom) and CN Biosciences (Nottingham,
United Kingdom).
Molecular Biology, Cell Culture, and
Transfection
Rat SNAT2 (Yao et al., 2000) and SNAT5 (Nakanishi et al.,
2001) cDNAs were placed in pcDNA6 (Invitrogen) following
PCR mutagenesis to introduce a C-terminal V5-His6 tag and
a SNAT2–SNAT5 NcoI chimera generated in pCR2.1 and
subcloned into pcDNA6 as described previously (Hyde et al.,
2007). For some experiments, the rat SNAT2 promoter (including
the first intronic element containing the tripartite AA responsive
domain) was subcloned into pC3luc (Hyde et al., 2007).
HeLa cells were transfected with pC3luc constructs (10 µg
DNA/10 cm plate) using calcium phosphate. Luciferase activity
was performed in 20 µg of cell lysate protein using the Luciferase
Assay System (Promega, United Kingdom) according to the
manufacturer’s instructions in a TD20/20 luminometer and
was standardized relative to serum-starved, AA-supplemented
cells.
HeLa cells were cultured in DMEM, supplemented with
10% FBS, and 1% (v/v) antibiotic/antimycotic solution
(100 units/ml penicillin, 100 mg/ml streptomycin, and 250 ng/ml
amphotericin B), at 37◦C with 5% CO2. HeLa cells were
incubated with HEPES-buffered saline [HBS; HEPES/NaCl
(140 mM NaCl, 20 mM HEPES, 5 mM KCl, 2.5 mM MgSO4,
1 mM CaCl2, and 5 mM glucose, pH 7.4] supplemented with
AA mix at 1× physiological concentration (Hyde et al.,
2001) for 1 h, rinsed and incubated in the appropriate
buffer for cell stimulation. In some experiments, Na+ salts
in HBS buffer were replaced with equimolar concentrations
of tetramethylammonium (TMA), N-methyl D-glucamine
(NMDG), or choline salts.
HeLa cells were transiently transfected with pcDNA6-
SNAT2V5, pcDNA6-SNAT5V5, pcDNA6-SNAT2-5V5 (10 µg
DNA/10 cm plate or 3.5 µg DNA/well of six-well plate) using
the polyethylenimine (PEI) method or in some experiments
with pcDNA6-7A-SNAT2V5 [a sequence in which the seven
lysine (K) residues in SNAT2 N-terminus were changed to
alanine (A)] (3 µg DNA/6-cm plate) using lipofectamine. The
7A-SNAT2V5 sequence was synthesized by Life Technologies
Geneart and the synthesized DNA was cloned into pcDNA6V5
plasmid via XhoI/XbaI digestion. It is important to stress
that for all transfection experiments, comparative analysis of
the effects that changes in substrate provision have upon
cellular SNAT abundance was performed on cells cultured in
plates/wells that were simultaneously transfected with the same
V5-tagged construct and, consequently, in which transfection
efficiency of plates/wells at the start of each experiment was
the same (∼40–50%). As a result, any changes in SNAT-V5
protein abundance that occur in response to manipulating
AA or Na+ availability is unlikely to be a consequence of
variations in transfection efficiency between tissue culture
plates/well.
RNA Extraction, qPCR, and shRNA
Total RNA was extracted from HeLa cells using TRIzol R© reagent
according to the manufacturer’s instructions (Sigma–Aldrich,
Poole, United Kingdom). Quantitative real-time PCR was carried
out using a StepOnePlus Real-Time PCR System (Applied
Biosystems), SYBR Green JumpStart Taq ReadyMix (Sigma–
Aldrich, Poole, United Kingdom), and primers targeting SNAT2
and SNAT5 with glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) being used as a control gene readout. The sequences
for SNAT2, SNAT5, and GAPDH primers were as follows:
SNAT2: forward, 5′-GCAGTGGAATCCTTGGGCTT-3′, SNAT2
reverse, 5′-ATAAAGACCCTCCTTCATTGGCA-3′; SNAT5:
forward, 5′-GAGAGGGTGCCCGAACCT-3′, reverse, 5′-CCTC
GAAATCCATGAACTGGAC-3′; GAPDH, forward, 5′-CCC
CCGGTTTCTATAAATTGAGC-3′, reverse, 5′-GACCAAATC
CGTTGACTCCGA-3′. PCR amplification was performed
with an initial denaturation at 95◦C for 10 min followed
by 40 cycles of denaturation at 95◦C for 15 s, annealing at
55◦C for 15 s, and extension at 68◦C for 1 min. The ratio of
the SNAT2 or SNAT5 mRNA expression to that of GAPDH
mRNA expression was calculated as described previously (Pfaﬄ,
2001).
The design and cloning of shRNA targeting Nedd4.2, lentiviral
production, and generation of a stable Nedd4.2 silenced HeLa cell
line was as previously described (Nardi et al., 2015).
Preparation of Total Cellular Membranes, Whole Cell
Lysates, and Immunoblotting
Following appropriate experimental treatments as described
in the text and figure legends, HeLa cells were rinsed twice
with ice-cold phosphate-buffered saline then extracted on
plates in lysis buffer containing 50 mmol/l Tris–HCl (pH
7.5), 1 mmol/l EDTA, 1 mmol/l EGTA, 1% (v/v) Triton X-
100, 1 mmol/l Na3VO4, 10 mmol/l sodium-glycerophosphate,
50 mmol/l NaF, 5 mmol/l Na4P2O7, 1 µmol/l microcystin-LR,
0.27 mol/l sucrose, 0.2 mmol/l phenylmethylsulfonyl fluoride,
1 mmol/l benzamidine, 10 µg/ml leupeptin, and 0.1% (v/v)
2-mercaptoethanol. Total cell membranes were isolated from
HeLa cells as described previously (Hajduch et al., 1998).
Protein concentration in cell lysates and membranes was
determined using the Bradford (1976) method. Proteins from
membranes (10 µg) and whole cell lysates (30 µg) were separated
on polyacrylamide resolving gels by SDS–PAGE. Proteins
were transferred onto PVDF membrane by immunoblotting
as described previously (Hajduch et al., 1998), and blocked
with 5% (w/v) milk in 0.05% (v/v) Tween 20/Tris-buffered
saline for 1 h. Membranes were then incubated overnight
with primary antibodies [as indicated in figure legends:
anti-Slc38a2 (SNAT2) was from MBL; anti-V5 was from
Invitrogen; anti-GAPDH and anti-β-actin from Sigma; anti-
Nedd4.2 was from Division of Signal Transduction and
Therapy, University of Dundee; α-subunit of the Na,K-
ATPase was from DSHB at the University of Iowa; anti-
insulin receptor β-subunit was from Abcam], and then
with an appropriate peroxidase-conjugated IgG for 1 h at
room temperature. Immunoreactive bands were detected by
enhanced chemiluminescence on Konica Minolta X-Ray film.
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FIGURE 1 | Effects of amino acid (AA) deprivation on Me-AIB uptake, SNAT2 mRNA, and SNAT2 protein abundance in HeLa cells. (A) HeLa cells were incubated in
the absence or presence of 1× physiological AA mix for 6 h and then subsequently maintained or re-exposed to a 1× AA mix for times indicated prior to analysis of
Me-AIB uptake. (B) Cells were incubated in the absence or presence of 1× physiological AA mix for 8 h or maintained in buffer in which the AA complement was
substituted with 2 mM Me-AIB. Cells were subsequently either used for analysis of 10 µM Me-AIB uptake or lysed for analysis of SNAT2 protein abundance by
immunoblotting with GAPDH used a loading control. (C) HeLa cells were transiently transfected with a pcDNA3 luciferase reporter construct, driven by the SNAT2
promoter; 48 h post-transfection cells were incubated in the absence (8 h) or presence of AAs. SNAT2 promoter activity was then determined by the analysis of
luciferase activity (luminescence quantification). Results calculated as relative luminescence (arbitrary units) per microgram of protein and normalized as a fold change
to a control value. Alternatively, following AA deprivation of cells SNAT2 mRNA was quantified using RT-PCR. (D) HeLa cells were AA deprived for 8 h and uptake of
10 µM [14C]-Me-AIB subsequently assessed in absence or presence of indicated AAs at 2 mM. Values are mean ± SEM from three to six separate experiments
with each uptake measure being assayed in triplicate in individual experiments. The asterisks indicate a significant difference from indicated bars P ≤ 0.05.
Quantification of immunoblots was performed using ImageJ
software1.
Amino Acid Uptake
After experimental treatments, HeLa cells were incubated with
10 µmol/l [14C]Me-AIB (1 µCi/ml) for 10 min to assay Me-
AIB uptake as previously described (Hajduch et al., 1998;
Hyde et al., 2007). Radiotracer uptake over this time period
was linear thus reflecting initial rates of uptake. Non-specific
tracer binding was quantified by determining cell-associated
radioactivity in the presence of a saturating dose of unlabeled
1http://rsbweb.nih.gov/ij/
Me-AIB (10 mM). To terminate uptake activity, cells were
washed three times with isotonic saline (0.9% NaCl, w/v) and
then lysed in 50 mM NaOH. Cell-associated radioactivity was
determined by liquid scintillation counting and standardized
to protein content determined using the Bradford (1976)
method.
Statistical Analyses
For multiple comparisons, statistical analysis was performed
using one-way ANOVA. For individual comparisons, statistical
analysis was performed using Student’s t-test. Data analysis
was performed using GraphPad Prism software and considered
statistically significant at P < 0.05.
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FIGURE 2 | Expression of SNAT2V5 in HeLa cells. (A) HeLa cells were transiently transfected with 5 or 10 µg pcDNA6 either lacking (empty vector, EV) or containing
SNAT2V5; 48 h post-transfection cells were lysed and whole cell lysates immunoblotted with antibodies to V5, SNAT2, and actin. (B) HeLa cells transiently
expressing SNAT2V5 were incubated in the absence or presence of 1× physiological AA mix for 8 h and then subsequently lysed and immunoblotted using
antibodies to V5 or the α1-subunit of the Na,K-ATPase (loading control). (C) Cells transfected with pcDNA6V5 (EV) or pcDNA6 containing SNAT2V5 were incubated
in the absence or presence of 1× physiological AA mix for 8 h prior assaying Me-AIB uptake. Uptake values are mean ± SEM from three separate experiments, each
conducted in triplicate. Asterisks indicate a significant difference between the indicated bars P ≤ 0.05.
FIGURE 3 | Substrate-induced regulation of SNAT2 stability. HeLa cells were transiently transfected with 10 µg of a pcDNA6 vector containing (A) SNAT2V5,
(B) SNAT5V5, or (C) SNAT2-5V5; 48 h post-transfection, cells were incubated for 8 h in the absence or presence of AAs or in EBSS containing 2 mM of the indicated
AA. Lysates (40 µg) were then subject to SDS–PAGE and immunoblotting with an anti-V5 antibody or antibody directed against actin, which was used as a gel
loading control. Blots are representative of three separate experiments, bar graphs values are mean ± SEM. V5 expression was quantified using ImageJ software
and results expressed as a fold change in expression of the transporter relative to that in cells incubated in the presence of AAs. Asterisks indicate a significant
difference between the indicated bars (P ≤ 0.05).
RESULTS AND DISCUSSION
Effects of Amino Acid Deprivation on
SNAT2 Activity and Expression
In line with our previous work in L6 myotubes (Hyde et al.,
2007), HeLa cells incubated in AA-free buffer exhibit a substantial
adaptive increase in Me-AIB uptake compared with cells held in
buffer containing a 1× physiological AA mix (Figure 1A). This
increase in Me-AIB uptake declined rapidly with a t1/2 of ∼3–
4 h upon re-exposing cells to AA-containing buffer. The adaptive
increase in Me-AIB transport activity was associated with an
increase in SNAT2 gene transcription (as judged by RT-PCR
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FIGURE 4 | Effects of the proteasomal inhibitor, MG132, and Nedd4.2 gene silencing on SNAT2 stability, and Me-AIB uptake in HeLa cells. (A) HeLa cells were
transiently transfected with 10 µg of a pcDNA6 vector containing SNAT2V5 and incubated in buffer containing AAs but lacking or supplemented with MG132
(10 µM) for 8 h. After this period cells were either lysed for analysis of SNAT2V5 by immunoblotting or used to assay Me-AIB uptake. (B) HeLa cells were incubated in
the absence or presence of 1× physiological AA mix for 8 h and then subsequently maintained or re-exposed to a 1× AA mix 6 h in the absence or presence of
10 µM MG132 prior to assaying Me-AIB uptake. Bar values (A and B) are mean ± SEM from three to five separate experiments with experiment conducted in
triplicate. Asterisks indicate a significant difference between indicated bars P ≤ 0.05. (C) HeLa cells stably expressing shRNA targeting Nedd4.2 or a control shRNA
(Scr) were incubated for 8 h in the absence or presence of AAs or in EBSS containing 2 mM of the indicated AA. Lysates (40 µg) were then subject to SDS–PAGE
and immunoblotting with an anti-V5 antibody or antibodies directed against Nedd4.2 or GAPDH, which was used as a gel loading control. (D) HeLa cells were
transiently transfected with 7KA-SNAT2V5 mutant, 24 h post-transfection cells were treated as in (C), and lysates immunoblotted with an anti-V5 antibody or
GAPDH antibody. The blot is representative of two similar experiments.
analysis of endogenous SNAT2 mRNA expression and increased
activity from an ectopically expressed SNAT2-luciferase gene
reporter construct) and an increase in native SNAT2 protein
content (Figures 1B,C) that was repressed in cells incubated
in buffer supplemented with Me-AIB alone (Figure 1C). As
anticipated, the functional increase in [14C]-Me-AIB uptake that
follows cellular adaptation to AA withdrawal was sensitive to
cis-inhibition when uptake of the radiotracer was assayed in the
presence of a competing concentration (2 mM) of unlabeled Me-
AIB, Ala, and Gln (Figure 1D). All three AAs are established
SNAT2 substrates suggesting that the measured increase in Me-
AIB uptake reflects an increase in functional activity of the
endogenous SNAT2 protein. Consistent with this suggestion
neither Tyr nor Leu (whose cellular uptake is not mediated via
SNAT2) had any significant inhibitory effect on the adaptive
increase in [14C]-Me-AIB uptake (Figure 1D). Since Me-AIB is
a non-metabolizable AA analog the above findings imply that the
transcriptional-dependent increase in endogenous SNAT2 seen
in AA-deprived cells is critically dependent upon whether SNAT2
is able to recognize/bind its substrate.
Use of a SNAT2V5 Construct to Explore
Substrate-Induced Changes in SNAT2
Stability
The data presented in Figure 1 are consistent with the idea
that the increase in SNAT2 activity in AA-deprived cells
involves a transcriptional response. However, we have also
shown previously that under these circumstances SNAT2 protein
can be stabilized post-translationally (Hyde et al., 2007), but
what remains unclear at present is whether this enhanced
stability is regulated in a substrate-dependent manner. To this
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FIGURE 5 | Effects of extracellular sodium replacement on Me-AIB uptake,
SNAT2, and SNAT5 gene expression. (A) Basal Me-AIB uptake was assayed
in HeLa cells using uptake buffer containing a physiological Na concentration
or one in which the cation was replaced with an equimolar concentration of
TMA. (B–D) HeLa cells were cultured in DMEM media and subsequently
incubated for 8 h in EBSS or buffer in which Na had been replaced with an
equimolar concentration of TMA that contained or lacked a 1× physiological
AA mix. Cells were subsequently washed and harvested for analysis of
SNAT2, SNAT5, and GAPDH gene expression by quantitative PCR analysis of
RNA (B,D) or analysis of SNAT2 protein (C) in total membranes isolated from
cells. Data in bar graphs are presented as mean ± SEM (n = 3) with asterisks
indicating significant changes (P < 0.05) between the indicated bars.
end, we transiently expressed a CMV-driven SNAT2 construct
(containing a C-terminal exofacial V5-His6 epitope tag) in a
pcDNA6 vector in HeLa cells. The CMV promoter lacks the AA-
responsive domain present in the SNAT2 gene and consequently
the SNAT2V5 transporter is expressed constitutively and any
changes in its abundance reflect changes in SNAT2 protein
stability alone. Figure 2A shows that a V5 immunoreactive band
could be detected in lysates of HeLa cells transfected with 5
or 10 µg of pcDNA6 containing the CMV-driven SNAT2V5
construct, but not in cells transfected with the empty vector.
The increased expression of SNAT2V5 in transfected cells could
also be detected using an anti-SNAT2 antibody that binds to
the endogenous and the V5-tagged transporter. Figure 2B shows
that while SNAT2V5 was detectable in HeLa cells transfected
with pcDNA6–SNAT2V5 when maintained in AA sufficient
media, the abundance of this ectopically expressed transporter
was elevated by approximately two-fold when cells were AA-
deprived for 8 h. Since expression of SNAT2V5 is driven by
an AA insensitive CMV promoter and transfection efficiency
between cells incubated in buffer containing or lacking AAs
was similar within each experiment, the elevated SNAT2V5
abundance induced upon AA deprivation is likely to reflect
increased stabilization of the carrier. This latter finding is
consistent with previous work from our lab (Hyde et al., 2007,
3143 /id), but we show here that the increase in SNAT2V5 is
also associated with a modest (∼30%) increase in Me-AIB uptake
over and above that recorded in control cells transfected with
the empty vector, in which, the elevated Me-AIB uptake elicited
by AA deprivation is due to the adaptive upregulation of the
endogenous SNAT2 transporter (Figure 2C).
Having established that SNAT2V5 is expressed and stabilized
within AA-deprived HeLa cells, we subsequently assessed
whether this increase in protein stability was sensitive to the
presence of SNAT2 substrates/non-substrates. HeLa cells were
transiently transfected with the CMV-driven SNAT2V5 construct
and subsequently incubated in the absence and presence of
Me-AIB, Gln, Tyr, or Leu during the AA deprivation period.
Figure 3A shows that compared with cells maintained in buffer
containing a 1× AA mix, SNAT2V5 protein abundance increased
by ∼1.6-fold upon incubating cells for 8 h in buffer lacking AAs.
Strikingly, this increase in SNAT2V5 protein was repressed if cells
were held in buffer containing 2 mM Me-AIB or Gln alone,
but not if these AAs were substituted with either Tyr or Leu.
This observation indicates that only SNAT2 substrates repress the
enhanced stability of SNAT2V5 under circumstances when the full
physiological AA complement is otherwise absent.
Unlike SNAT2, SNAT5 [a closely related SLC38 member of
the System N family (Mackenzie and Erickson, 2004)] does
not exhibit AA-regulated transcriptional upregulation nor is
the stability of this transporter modified post-translationally
(Hyde et al., 2007). Consistent with these previous observations,
Figure 3B shows that SNAT5V5 protein abundance was not
altered significantly when cells expressing this construct were
deprived of AAs or maintained in buffer containing the indicated
AAs. We have previously shown that the increase in SNAT2
stability seen upon AA withdrawal is associated with an isoform-
specific regulatory domain(s) present within the hydrophilic
N-terminal region, because “substituting” the corresponding
N-terminal region of SNAT5 with that of SNAT2 stabilized
the chimeric SNAT2-5V5 protein upon AA withdrawal (Hyde
et al., 2007; Figure 3C). Intriguingly, this stabilization can be
repressed by resupply of Gln, but not Me-AIB, Tyr, or Leu
(which importantly are not SNAT5 substrates). This observation
indicates that the N-terminal domain of SNAT2 confers a
stabilization signal in the absence of substrates and significantly,
that transporter stability is mechanistically linked to substrate
binding and/or translocation.
SNAT2 Stability Is Not Regulated by
Nedd4.2 but Is Dependent on Putative
Lysyl Ubiquitination Residues within the
N-Terminal Tail
The proteasome inhibitor MG132 has been shown to increase
SNAT2 transport activity in 3T3-L1 adipocytes under AA
sufficient conditions, suggesting that steady-state levels of the
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FIGURE 6 | Effects of changes in extracellular sodium on native SNAT2 protein expression in HeLa cells. (A) HeLa cells were maintained in the absence or presence
of a 1× physiological AA mix for 8 h in HEPES buffer (HBS) containing 140 mM NaCl (Na-HBS). Cells were either harvested or incubated for a further 4 or 6 h in
AA-deficient Na-HBS, or HBS in which NaCl was replaced with 50 or 100% TMACl. At the end of these periods cells were harvested and total membranes (10 µg)
prepared, which were subjected to SDS–PAGE and were then immunoblotted with antibodies against SNAT2 or the beta-subunit of the insulin receptor (IRβ).
(B) HeLa cells were incubated for an initial 8 h with or without a 1× AA mix in Na-HBS and then harvested or incubated for an additional 6 h without AAs in a partial
(50%) sodium-replaced, or fully (100%) sodium-replaced HBS media. Sodium was partially or fully replaced with either TMA, NMDG, or choline. At the end of the
indicated incubation periods indicated, cells were harvested and total membranes (10 µg) prepared before SDS–PAGE and immunoblotting against SNAT2 and IRβ
(used as a loading control). Endogenous SNAT2 expression was quantified using ImageJ software and results expressed as relative abundance with respect to the
IRβ. Blots are representative of three separate experiments, bar graphs values are mean ± SEM (n = 3). Asterisks indicate a significant difference between the
indicated bars (P ≤ 0.05).
transporter may be influenced by the ubiquitin-proteasome
system (UPS) (Hatanaka et al., 2006). Indeed, the ubiquitin E3-
ligase Nedd4.2 has been implicated as a regulator of SNAT2
ubiquitination (Hatanaka et al., 2006). To assess whether
proteasomal activity features in the substrate-induced regulation
of SNAT2 transporter stability, we assessed what impact MG132
has upon SNAT2-mediated transport under (i) AA sufficient
conditions and (ii) upon resupply of AAs to cells that had been
subject to a period of AA deprivation. Figure 4A shows that
HeLa cells transiently transfected with SNAT2V5 exhibit greater
SNAT2V5 protein expression under AA-sufficient conditions
when incubated with 10 µM MG132 for 8 h than those exposed
to vehicle solution alone and also that this coincides with a
significant increase in Me-AIB uptake. In line with the data
shown in Figure 1A, in normal untransfected HeLa cells, AA
withdrawal for an 8-h period induced a robust adaptive increase
in Me-AIB uptake, which was repressed to near base line values
upon AA resupplementation for 6 h (Figure 4B). However,
this repression was significantly blunted if MG132 was present
during the AA resupply period (Figure 4B). This observation
implies that proteasomal inhibition with MG132 may restrain
degradation of endogenous SNAT2 and, by doing so, help
preserve a greater component of the SNAT2-mediated transport
activity that is otherwise rapidly lost upon resupplying AAs
to cells previously subjected to AA deprivation. In support of
this idea, we recently reported that SNAT2 exhibits greater
ubiquitination when AAs are present in the culture buffer and
is thus more likely to be degraded by the UPS under these
circumstances then when AAs are absent. Rapid turnover of
SNAT2 protein involving the UPS would therefore help maintain
relatively low levels of SNAT2 protein and transport activity in
AA-replete cells (Nardi et al., 2015). Since MG132 is unlikely
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FIGURE 7 | Effects of Na replacement and MG132 on endogenous SNAT2
protein stability. HeLa cells were maintained in the absence or presence of a
1× physiological AA mix for 8 h in HBS containing 140 mM NaCl (Na-HBS).
Cells were either harvested or incubated for a further 4 or 6 h in AA-deficient
buffer containing cycloheximide (50 µg/ml). This buffer either contained
140 mM Na+ or the cation was fully replaced with NMDG or was replaced
with buffer containing NMDG supplemented with MG132 (10 µM). At the end
of the initial 8 h or the extended 4 and 6 h AA deprivation periods cells were
harvested and total membranes prepared and 10 µg membrane protein
subjected to SDS–PAGE prior to immunoblotting with antibodies against
native SNAT2 or the beta-subunit of the insulin receptor (IRβ). Endogenous
SNAT2 expression was quantified using ImageJ software and results
expressed as relative abundance with respect to the IRβ. Blots are
representative of three separate experiments, bar graphs values are
mean ± SEM. Asterisks indicate a significant difference between the indicated
bars (P ≤ 0.05).
to curtail internalization and lysosomal-directed degradation of
SNAT2 carriers from the cell surface, it is not surprising that
the inhibitor does not completely attenuate the AA-induced
repression of SNAT2 transport activity (Figure 4B).
To test whether Nedd4.2 participates in the substrate-
induced destabilization of SNAT2, we generated HeLa cells
in which Nedd4.2 had been stably silenced using a lentiviral
shRNA strategy (Nardi et al., 2015). Figure 4C shows that
HeLa cells exhibit enhanced stabilization of SNAT2V5 upon
AA deprivation which was repressed in a substrate-dependent
manner irrespective of whether Nedd4.2 was present or if its
expression had been substantially depleted by gene silencing;
an observation that appears to exclude Nedd4.2 as a regulator
of SNAT2 stability in our cell system. Since “grafting” the
N-terminal domain of SNAT2 onto SNAT5 bestows substrate-
dependent changes in stability upon a SNAT2–5 chimeric protein,
we postulated that this domain was most likely targeted for
ubiquitination by an unidentified E3-ligase. Ubiquitination of
substrate proteins is canonically targeted at lysyl residues and
it is noteworthy that a number of cell surface transporters
[e.g., epithelial Na+ channel (ENaC) and neurotransmitter
transporters including those for AAs such as γ-aminobutyric
acid (GABA), glutamate, and glycine] are ubiquitinated on
lysyl residues within their N-terminal domains (Staub et al.,
1997; Sheldon et al., 2008). Ubiquitination of cell surface
proteins is recognized as a common mechanism promoting
internalization and endosomal sorting that results in either
their recycling back to the plasma membrane or targeting
to the proteasome or lysosome for degradation [reviewed in
Miranda and Sorkin (2007)]. Much like the above transporters,
the N-terminal domain of SNAT2 possesses seven putative
lysyl ubiquitination targets. We therefore expressed a SNAT2V5
construct in which all seven of these lysyl residues were
mutated to alanine (7A-SNAT2V5). Figure 4D shows that,
unlike wild-type SNAT2 (Figure 4C), the stability of the 7A-
SNAT2V5 protein is not modified by changes in AA availability
nor is it sensitive to substrate-induced destabilization. Since
the 7A-SNAT2V5 protein is equally stable under the different
conditions tested, we argue that binding of AA substrates to
the native transporter may induce a conformational change in
the protein that make one or more of the target lysyl residues
in the N-terminal SNAT2 domain accessible for ubiquitination
by its E3-ligase that then promotes ubiquitinated SNAT2
internalization/degradation.
The Role of Na+ in Regulating
Transcriptional and Post-translational
Aspects of the SNAT2 Adaptive
Response
Amino acid uptake via SNAT2 is critically dependent upon the
availability of Na+ as a co-substrate and previous studies have
identified helices 1 and 8 as being important for accommodating
the Na+ binding site, given that mutation of Asn82 and
Thr384, respectively, located within these helices reduces the
transporter’s affinity for Na+ and its capacity for mediating AA
transport (Zhang et al., 2008, 2009). However, to our knowledge,
the importance of Na+ as a determinant of the SNAT2
adaptive/stability response has not been previously addressed. In
line with the importance of Na+ as a co-substrate, replacement
of extracellular NaCl with TMACl was found to virtually abolish
cellular Me-AIB uptake (Figure 5A). As anticipated, subjecting
HeLa cells to AA deprivation for 8 h induced a significant increase
in mRNA abundance of the endogenous SNAT2 transporter,
but this was not seen when cells were AA deprived for this
period in TMACl-containing buffer (Figure 5B). In line with
this observation, analysis of native SNAT2 protein expression
revealed a strong increase in the abundance of the endogenous
transporter when cells were AA deprived, but this response
was absent if cells were AA deprived in buffer also lacking
Na+ (Figure 5C). In contrast, the transcriptional expression of
endogenous SNAT5, a related Na+-coupled AA transporter, was
unaltered in response to AA insufficiency and was marginally,
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FIGURE 8 | Effects of changes in extracellular AA availability and sodium on transiently expressed SNAT2V5 protein stability in HeLa cells. HeLa cells were transiently
transfected with 10 µg of a pcDNA6 vector containing SNAT2V5 and subsequently incubated in (A) HBS containing 140 mM NaCl or (B) buffer in which NaCl had
been replaced with TMACl for 8 h in the absence or presence of AAs or with the appropriate HBS or TMACl buffer containing 2 mM of the indicated AA.
(C) Forty-eight hours post-transfection a population of SNAT2V5 transfected cells maintained in AA-containing HBS buffer was either lysed or subsequently washed
“free” of HBS and then incubated for a further 6 h in AA-containing buffer in which NaCl had been replaced with TMACl prior to lysis. Lysates (A–C) (40 µg) were
then subject to SDS–PAGE and immunoblotting with an anti-V5 antibody or antibody directed against actin, which was used as a gel loading control. Blots are
representative of three separate experiments, bar graphs values are mean ± SEM. V5 expression was quantified using ImageJ software and results expressed as a
fold change in expression of the transporter relative to that in cells incubated in the presence of AAs. Asterisks indicate a significant difference between the indicated
bars (P ≤ 0.05).
but not significantly, elevated in response to extracellular Na+
withdrawal (Figure 5D).
Following these observations, we subsequently assessed the
effects of removing extracellular Na+ upon protein expression
of the native SNAT2 transporter expressed in HeLa cells using
two different strategies. The first involved subjecting HeLa cells
to an initial 8 h period of AA deprivation in media containing
a physiological Na+ concentration (140 mM). At the end of
this period, cells were either harvested (for isolation of total
cell membranes) or maintained for a further period (4 or
6 h) in AA-free buffer in which Na+ was present at 100, 50,
or 0% of its physiological concentration (using TMA as the
cation replacement). At the end of each of these additional
incubation periods, cells were harvested and total membranes
isolated and the abundance of endogenous SNAT2 determined
by immunoblotting. Figure 6A shows that 8 h of AA deprivation
induced a notable elevation in native SNAT2 protein abundance,
which was further elevated in a time-dependent manner if cells
were subjected to an extended period of AA deprivation in
Na+-containing buffer for up to 14 h. However, this increase
in endogenous SNAT2 was blunted if the AA-free media during
the extended period contained 50% of the physiological Na+
concentration and absent if the Na+ was completely replaced
with TMA. In contrast to effects on SNAT2, manipulating the
AA or Na+ content of the extracellular buffer had no detectable
effect on the membrane abundance of the insulin receptor beta-
subunit, which was used as a gel loading control (Figure 6A). To
exclude the possibility that these effects on endogenous SNAT2
protein abundance were induced by TMA through a mechanism
that acts independently of its role as a Na+ cation replacement, we
also assessed the effects of using NMDG and choline as Na+ ion
replacements. As with TMA, Figure 6B shows that replacing Na+
with either of these two cations led to a concentration-dependent
reduction in native SNAT2 protein abundance despite cells being
maintained in AA-deprived buffer.
The decline in SNAT2 protein seen upon incubating cells
in an environment with reduced Na+ may not just reflect a
failure to sustain the adaptive increase in SNAT2 gene expression
under AA-insufficient conditions, but also a reduction in SNAT2
protein stability. To assess whether Na+ may be an important
determinant of SNAT2 stability, two additional experimental
strategies were employed.
The first involved subjecting HeLa cells to an 8-h period of
AA deprivation to induce the characteristic adaptive increase
in SNAT2 protein expression. After this period, cells were
washed and incubated for a further 4 or 6 h in AA-free buffer
containing cycloheximide (CHX) so as to block further synthesis
of native SNAT2 protein that is driven by the increased expression
of the endogenous SNAT2 gene. During this extended AA
deprivation period the incubation buffer either contains Na+ at
a physiological concentration or was fully replaced with NMDG.
At the end of the extended 4 or 6 h AA deprivation period,
total membranes from HeLa cells were prepared and endogenous
SNAT2 protein content assessed by immunoblotting. Figure 7
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shows that AA deprivation for 8 h induces a robust increase
in native SNAT2 abundance (compare lanes 1 and 2), but that
this subsequently declines if synthesis of new SNAT2 protein
was halted by CHX despite the absence of AA in the buffer
(compare lanes 2, 3, and 6). This decline most likely reflects
degradation of endogenous SNAT2 and our data indicate that
this loss was significantly accelerated if extracellular Na+ was
replaced with NMDG (compare lanes 3 and 4; lanes 6 and 7). This
proposition is further strengthened by the demonstration that we
can attenuate the rapid loss in native SNAT2 protein induced by
extracellular Na+ removal by supplementing the Na-free buffer
with the proteasomal inhibitor, MG132 (compare lanes 4 and 5;
lanes 7 and 8).
The second strategy utilized the transient expression of
SNAT2V5 in HeLa cells. In line with the data presented in
Figure 3A, depriving cells of AAs in buffer containing a
physiological Na+ concentration induced a significant increase
in SNAT2V5 stability, which was not observed if Gln or Me-
AIB (SNAT2 substrates) were present in the buffer whereas
presence of Tyr or Leu (non-substrates) did not restrain the
increased stabilization of the transporter (Figure 8A). Strikingly,
expression of SNAT2V5 or evidence of its stabilization in response
to AA deprivation was not evident if cells transfected with
the pcDNA6–SNAT2V5 were incubated in TMACl-containing
buffer for 8 h prior to immunoblot analysis (Figure 8B).
While it is possible that extracellular Na+ replacement may
have suppressed expression of the CMV-driven SNAT2V5
construct, we considered it was more likely that replacement of
extracellular Na+ from cells in which the transporter construct
had initially been expressed under Na+ replete conditions
may have led to rapid degradation of the transporter protein.
To test this, cells transfected with pcDNA6–SNATV5 in Na+
containing buffer were split into two subpopulations 48 h
post-transfection. One population was immediately lysed and
immunoblotted to confirm the expression of the V5-tagged
transporter, while the other was washed and subsequently
maintained, for a further 6 h, in buffer in which sodium had
been replaced with TMA prior to immunoblotting. Figure 8C
shows that while SNAT2V5 was readily detectable in the
first population of cells that were held in Na+-containing
buffer, the transporter was barely detectable in the second
population of cells (from the same transfection experiment) when
subsequently incubated in buffer in which Na+ was completely
replaced by TMA. Both endogenous SNAT2 and transiently
overexpressed SNATV5 exhibit similar protein instability in
the absence of Na+. Based on these observations it might
have been anticipated that previous studies in which SNAT2
residues implicated in Na+ binding (Asn82 and Thr384) had
been mutated may have reported reduced expression/stability
of the carrier. However, immunofluorescence and cell surface
biotinylation analysis of SNAT2 harboring mutations at these
residues suggests that membrane expression of the mutated
transporter is maintained (Zhang et al., 2008, 2009). Since
mutation of Asn82 and Thr384 is associated with reduced
carrier affinity rather than loss in Na+ binding per se, it is
possible that despite the reduced cation affinity, the presence
and binding of Na+ may be sufficient to help sustain SNAT2
expression/stability. We speculate that the binding of Na+
to SNAT2 (endogenous or ectopically expressed) in the cell
membrane imposes a stabilized (N-terminal tail occluded)
conformation and that, in the additional presence of AA,
substrate-induced cycling of the transporter periodically exposes
the N-terminus for ubiquitination when substrates are released
and thus reduces protein stability. In the absence of either Na+ or
AA substrates, the exposed N-terminal conformation maximizes
the likelihood of SNAT2 protein ubiquitination and subsequent
proteolysis.
CONCLUSION
Collectively, the findings presented herein imply that while
SNAT2-mediated AA uptake is substantially reduced in Na+-
free buffer; a scenario that would essentially mimic a state of
AA deprivation, sensing of SNAT2 substrate insufficiency and
its coupling to the transcriptional activation of the SNAT2 gene
and to processes regulating carrier stability is crucially dependent
on the presence and perhaps binding of extracellular Na+ to
the transporter. While these observations further strengthen
the concept that SNAT2 possesses transceptor-like functions,
precisely how substrate occupancy/transport is mechanistically
linked to molecules that regulate its cellular expression and
protein turnover is unclear and remains important investigative
goals of future work.
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